Person: DİNÇ, HARİKA ÖYKÜ
Loading...
Status
Kurumdan Ayrılmıştır.
Organizational Units
55 results
Search Results
Now showing 1 - 10 of 55
Publication Open Access Antibody Response to SARS-CoV-2 Vaccines in People with Severe Obesity(2022-07-01T00:00:00Z) KARA, ZEHRA; Akcin, Ruveyda; DEMİR, Ahmet Numan; DİNÇ, HARİKA ÖYKÜ; Taskin, Halit Eren; KOCAZEYBEK, BEKİR SAMİ; YUMUK, VOLKAN DEMİRHAN; DİNÇ, HARİKA ÖYKÜAim: Obesity is a disease complicating the course of COVID-19 and SARS-CoV-2 vaccine effectiveness in adults with obesity may be compromised. Our aim is to investigate the spike-protein receptor-binding domain antibody titers against BNT162b2 mRNA and inactivated SARS-CoV-2 (CoronaVac) vaccines in people with severe obesity. It is anticipated that the results to be obtained may provide invaluable information about future SARS-CoV-2 vaccination strategies in this vulnerable population. Methods: A total of 124 consecutive patients with severe obesity (age > 18 years, BMI ≥ 40 kg/m2) presenting between August and November 2021 were enrolled. The normal weight control group (age > 18, BMI 18.5-24.9 kg/m2) was recruited from 166 subjects who visited the vaccination unit. SARS-CoV-2 spike-protein antibody titers were measured in patients with severe obesity and in normal weight controls who received two doses of BNT162b2, or CoronaVac vaccines. SARS-CoV-2 IgG Nucleocapsid Protein antibody (NCP Ab) testing was performed to discover prior SARS-CoV-2 infection. Blood samples were taken from individuals at 4th week and after 2nd dose of vaccination. SARS-CoV-2 IgG antibody titers were determined by quantitative serological methods. Results: A total of 290 individuals (220 female, 70 male) who have received two doses of BNT162b2 or CoronaVac vaccines were enrolled in the study. Seventy had prior SARS-CoV-2 infection. In 220 subjects (non-prior infection) vaccinated with BNT162b2 or CoronaVac, the antibody titers against SARS-CoV-2 spike antigen of patients with severe obesity were significantly lower than normal weight controls (p = 0.001, p = 0.001 respectively). In seventy subjects with prior SARS-CoV-2 infection, spike antigen antibody titers in patients with severe obesity, vaccinated with BNT162b2 or CoronaVac, were not significantly different from normal weight controls (p = 0.1, p = 0.1 respectively). In patients with severe obesity, with and without prior SARS-CoV-2 infection, spike antigen antibody levels of those vaccinated with BNT162b2 were found to be significantly higher than those vaccinated with CoronaVac (p = 0.043, p < 0.001 respectively). Conclusion: Patients with severe obesity generated significantly reduced antibody titers against SARS-CoV-2 spike antigen after CoronaVac and BNT162b2 vaccines compared to people with normal weight. Antibody levels in patients with severe obesity vaccinated with BNT162b2 were found to be significantly higher than those vaccinated with CoronaVac. People living with severe obesity should be prioritized for COVID-19 vaccination and BNT162b2 vaccine may be recommended for this vulnerable population.Publication Metadata only Waning of SARS-CoV-2 Vaccine-Induced Immune Response over 6 Months in Peritoneal Dialysis Patients and the Role of a Booster Dose in Maintaining Seropositivity(2022-05-01T00:00:00Z) Murt, Ahmet; Dinc, HARİKA ÖYKÜ; Altiparmak, Mehmet Riza; Yalin, Serkan F.; Yadigar, Serap; Parmaksiz, Ergun; Kocazeybek, Bekir; Pekpak, Meltem; Ataman, Muveddet Rezzan; DİNÇ, HARİKA ÖYKÜIntroduction: Although lower than general population, newly developed SARS-CoV-2 vaccines generate immune responses in end-stage kidney disease patients. However, the persistence of immune responses in the long term is not known yet. This study aimed to evaluate humoral immune responses in peritoneal dialysis (PD) patients over 6 months and to analyze the effects of the booster dose. Methods: Humoral immune responses of PD patients were measured after initial SARS-CoV-2 vaccinations and after 6 months following initial vaccinations. Immune responses were compared between patients who received and did not receive booster doses. PD patients were compared with 41 hemodialysis (HD) patients and 61 healthy controls. Humoral immune responses were measured by a commercial test that detects antibodies toward the receptor-binding domain of the spike protein of SARS-CoV-2. Results: Twenty PD patients were evaluated over 6 months. The initial seropositivity rate was 90.9% with inactivated vaccine and 100% with mRNA vaccine. Seropositivity decreased to 44.4% after 6 months, and a booster dose helped in maintaining the 100% of seropositivity (p = 0.005). Magnitude of humoral response at the 6th month was also higher in patients who received the third dose (1,132.8 +/- 769.6 AU/mL vs. 400.0 +/- 294.6 AU/mL; p = 0.015). Among patients who did not receive the third dose, those who got mRNA vaccine could maintain higher seropositivity than others who got inactivated vaccine (75% vs. 40% for PD, 81.8% vs. 50% for HD). Seropositivity and antibody levels were similar for PD and HD patients after 6 months (p = 0.24 and 0.56) but lower than healthy controls (p = 0.0013). Conclusion: SARS-CoV-2 vaccine-induced antibody levels and seropositivity of PD patients significantly fall after 6 months. A booster dose after around 3 months following initial immunization might help in maintaining seropositivity.Publication Metadata only Risk factors influencing seroconversion after inactive SARS-CoV-2 vaccination in people living with obesity(2022-08-01T00:00:00Z) KARA, ZEHRA; Akcin, Rueveyda; DEMİR, Ahmet Numan; Dinc, Harika Oyku; KOCAZEYBEK, BEKİR SAMİ; YUMUK, VOLKAN DEMİRHAN; DİNÇ, HARİKA ÖYKÜIntroductionPublication Open Access Investigation of Bioactive Components, Antioxidant and Antimicrobial Activities of Traditional Turkish Beverage Hardaliye(2022-01-01T00:00:00Z) POLAT SARI, SİLVA; DİNÇ, HARİKA ÖYKÜ; BÜYÜKKILIÇ ALTINBAŞAK, BETÜL; YÜKSEL MAYDA, PELİN; AKGÜL, ÖZER; SAPMAZ, BURCU; ÖNER, YAŞAR ALİ; ÇALIŞKAN, REYHAN; DİNÇ, HARİKA ÖYKÜ; BÜYÜKKILIÇ ALTINBAŞAK, BETÜLObjective: In our study, it was aimed to make the chemical analysis of hardaliye products (H1 and H2), which are commercially available by different manufacturers, and to examine their antioxidant and antimicrobial activities. Methods: Antioxidant activity, organic acid and phenolic compounds, and antimicrobial activity in Hardaliye products (H1 and H2) were determined by using 1.1-diphenyl-2-picrylhydrazyl (DPPH) free radical scavenging activity, [liquid chromatographyhigh resolution mass spectrometry (LC-HR/MS)] and liquid microdilution methods, respectively. Results: Ascorbic acid and fumaric acid from organic acids were determined by chemical analysis of hardaliye samples by LC-HR/ MS method. While ascorbic acid concentrations were 21.295 mg/L and 26.84 mg/L in H1 and H2, respectively, fumaric acid concentrations were 59.55 mg/L in H1, and 224.562 mg/L in H2. While the phenolic component with the highest concentration in H1 was resveratrol (44.57 mg/L), it was observed that the phenolic component with the highest concentration in H2 was p-coumaric acid (31.87 mg/L). In terms of antioxidant activity, diphenyl-2- picrylhydrazylfree radical scavenging activity of hardaliye samples was determined as 2.07±0.004% and 2.49±0.004% in H1 and H2, respectively. It was determined that hardaliye samples showed inhibitory effect [H1 minimum inhibitor concentration (MIC): 15.625 µg/mL, H2 MIC: <3.9 µg/mL] against only S. Epidermidis ATCC 49461 strains among the tested microorganisms. Conclusion: In our study, it was determined that two different commercial Hardaliye products contained very low concentrations of phenolic compounds compared to the data in the literature, and therefore it was thought that tested Hardaliye products did not show antioxidant activity.Publication Open Access Inactive SARS-CoV-2 vaccine generates high antibody responses in healthcare workers with and without prior infection.(2021-11-22T00:00:00Z) Dinc, HARİKA ÖYKÜ; Saltoglu, Nese; Can, Gunay; Balkan, Ilker Inanc; Budak, Beyhan; Ozbey, Dogukan; Caglar, Bilge; Karaali, Rıdvan; Mete, Bilgul; Tuyji Tok, Yesim; Ersoy, Yagmur; Ahmet Kuskucu, Mert; Midilli, Kenan; Ergin, Sevgi; Kocazeybek, Bekir Sami; DİNÇ, HARİKA ÖYKÜBackground and objectives: Healthcare workers (HCWs) were among the first groups to be vaccinated in Turkey. The data to be obtained by the vaccination of HCWs would guide wide spread vaccination programs. Materials and methods: The study included 330 HCWs working at Istanbul University-Cerrahpaşa, Cerrahpaşa Medical Faculty Hospital and vaccinated with inactive CoronaVac (Sinovac Life Sciences, China) SARS-CoV-2 vaccine in two doses (28 days apart). Anti-Spike /RBD IgG levels were measured 14 days after the first dose and 28 days after the second dose. Chemiluminescent microparticle immunoassay (CMIA) (ARCHITECT IgG II Quant test, Abbott, USA), which is 100% compatible with plaque reduction neutralization test (PRNT), was used. Results: Of the participants, 211 (63.9%) were female, 119 (36.1%) were male, and mean age was 39.6 ± 7.7 years. In those without prior COVID-19 history; (n = 255) antibody positivity was detected as 48.2% (95% CI: 42.1-54.3) 14 days after the first dose of vaccine, and 99.2% (95% CI: 98.1-100) at day 28 after the second dose. Antibody titers were significantly lower in patients with hypertension (p = 0.011). In those with prior history of COVID-19 (n = 75); both the antibody positivity rates after the first vaccine (48.2% vs 100%, p = 0.000) and the anti-spike/RBD antibody levels after the second vaccine (with a ≥ 1050 AU/mL titer equivalent to PRNT 1/80 dilution) was significant than infection-naive group (25.9% vs. 54.7%, p = 0.000). Antibody positivity after two doses of vaccination for all study group was 99.4% (95% CI: 98.6-100). Conclusions: Two doses CoronaVac produce effective humoral immunity in HCWs. Antibody response is significantly higher in those with prior history of COVID-19 than infection-naive group. Given no significant benefit of the second dose, a single shot of vaccination may be sufficient for those with prior history of COVID-19. Monitoring humoral and cellular immune responses, considering new variants, is required to validate this approach.Publication Metadata only Retrospective Evaluation of Toxoplasma gondii, Rubella and Cytomegalovirus Seropositivity and Avidity Test Results in Patients Admitted to İU-C Cerrahpaşa Medical Faculty Hospital Between 2013-2018(2020-01-01T00:00:00Z) Demir, Esra; DİNÇ, HARİKA ÖYKÜ; Özbey, Doğukan; AKKUŞ, SEHER; ERGİN, SEVGİ; KOCAZEYBEK, BEKİR SAMİ; DİNÇ, HARİKA ÖYKÜPublication Open Access Heterologous booster COVID-19 vaccination elicited potent immune responses in HCWs(2022-10-01T00:00:00Z) SALTOĞLU, NEŞE; DİNÇ, HARİKA ÖYKÜ; BALKAN, İLKER İNANÇ; CAN, GÜNAY; Ozbey, Dogukan; BEYTUR, AYŞE NUR; KESKİN, ELİF; BUDAK, Beyhan; Aydogan, Okan; METE, BİLGÜL; KARAALİ, RIDVAN; ERGİN, SEVGİ; KOCAZEYBEK, BEKİR SAMİ; DİNÇ, HARİKA ÖYKÜThe objective of our study was to evaluate the antibody responses of health care workers (HCWs) who were vaccinated with booster dose BNT162b2 6 months after 2 doses of the CoronoVac vaccine. The study included 318 HCWs vaccinated with inactive CoronaVac SARS-CoV-2 vaccine in 2 doses. Anti-spike/RBD IgG levels were measured immediately before and 1 month after the booster dose. In the sixth month after Coro-naVac vaccination, the median of antibody levels of 1212.02 AU/ML, while it was 9283 AU/mL after BNT162b2 vaccination. IgG antibody titers of over 1050 AU/mL (which is equivalent to 1:80 dilution in the plaque reduction neutralization test) were detected in HCWs 15.09% and 97.8%, respectively. Our results showed that antibody titers increased 8-fold after the booster dose. We believe that the administration of the mRNA vaccine as a booster dose can provide more effective protection against COVID-19 infection, espe-cially in individuals with risk factors.Publication Metadata only BIOACTIVE COMPONENTS AND ANTIOXIDANT AND ANTIMICROBIAL ACTIVITY OF RHUS CORIARIA SPECIES OF SUMAC IN TURKEY(2022-02-18T00:00:00Z) Yüksel Mayda, Pelin; Polat, Silva; Büyükkılıç Altınbaşak, Betül; Dinç, Harika Öykü; Çalışkan, Reyhan; BÜYÜKKILIÇ ALTINBAŞAK, BETÜL; DİNÇ, HARİKA ÖYKÜPublication Metadata only The prevalence of periodontal pathogenic bacteria in atherosclerotic cardiovascular disease(2020-01-01T00:00:00Z) Gode, Safa; Sarp, Tevhide Z.; Saribas, Suat; Ergin, Sevgi; Kasnak, Gökhan; Dinc, HARİKA ÖYKÜ; Caliskan, Reyhan; Akkus, Seher; Tokman, Hrisi B.; Kocak, Banu T.; Demirci, Mehmet; Gareayaghi, Nesrin; Kirmusaoglu, Sahra; Tokman, Halit; Kocazeybek, Bekir; DİNÇ, HARİKA ÖYKÜPublication Metadata only BİR ÜNİVERSİTE HASTANESİNDE YATAN HASTALARDAİNFEKSİYON/KOLONİZASYON YÖNÜNDEN RİSK FAKTÖRLERİNİN DAĞILIMI(2017-03-22T00:00:00Z) KURT, AYKUT; DİNÇ, HARİKA ÖYKÜ; Küçük Aydın, Nida; BALKAN, İLKER İNANÇ; SALTOĞLU, NEŞE; cengiz, serpil; alisha, lütfiye; AYGÜN, GÖKHAN; DİNÇ, HARİKA ÖYKÜ